Back to top
more

Akero Therapeutics (AKRO)

(Real Time Quote from BATS)

$18.99 USD

18.99
576,887

-1.27 (-6.27%)

Updated Apr 25, 2024 03:49 PM ET

After-Market: $18.92 -0.07 (-0.37%) 4:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for AKRO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Akero Therapeutics, Inc. [AKRO]

Reports for Purchase

Showing records 1 - 20 ( 105 total )

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/05/2024

Company Report

Pages: 10

96-Week HARMONY Data Demonstrates Unprecedented Fibrosis Improvement; Strong Validation for SYNCHRONY; Raise PT to $50

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

03/01/2024

Company Report

Pages: 8

4Q Recap: 96-Week Results From Phase 2b HARMONY on Monday; EOP2 Meeting to Set the Tone for 2024; Raise PT to $43

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

01/31/2024

Daily Note

Pages: 114

2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

01/30/2024

Daily Note

Pages: 115

2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

01/23/2024

Industry Report

Pages: 6

Enter a New Key Challenger in the MASH Race: Sagimet''s Denifanstat Looks to Enter Phase 3 by YE24

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

12/19/2023

Daily Note

Pages: 4

Phase 3 SYNCHRONY Program Underway; Next Quarter Is Key With Two Major Milestones For EFX; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

11/21/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for AKRO 112123

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

11/14/2023

Company Report

Pages: 8

3Q Recap; EFX to Enter Pivotal Trials Imminently; SYNCHRONY on Target to Enroll First Patient By YE23; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

10/11/2023

Company Report

Pages: 9

Surprise Miss on 36-Week Fibrosis Improvement in Cirrhotic NASH Complicates the Regulatory Path Forward; PT to $40

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

10/05/2023

Daily Note

Pages: 8

Phase 2b HARMONY Dataset Provides Exhaustive Review of EFX; Phase 2b SYMMETRY Top-Line Readout This Month; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

08/14/2023

Company Report

Pages: 9

2Q Recap; SYMMETRY Data in Cirrhotic Patients On Target in 4Q23; Initiations of SYNCHRONY Studies in 2H23; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

06/07/2023

Company Report

Pages: 13

EFX + GLP-1 Combo Offers Substantial Benefit Over GLP-1s Alone, Exceeding Our Expectations; Raise PT to $64

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

05/16/2023

Company Report

Pages: 9

1Q Recap; SYMMETRY Cohort D Data On Target in 2Q23; Phase 3 SYNCHRONY Program Initiating in 2H23; Moderate PT to $62

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

03/31/2023

Daily Note

Pages: 6

4Q Recap; NAVIGATE Phase 2b Interim Analysis On Target in 4Q24; Exploring Belapectin Oncology Opportunities; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

03/20/2023

Company Report

Pages: 8

4Q Recap; SYMMETRY Cohort D Data in 2Q23; FDA Meeting This Month to Determine EFX Phase 3 Study Design; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

12/23/2022

Daily Note

Pages: 4

Phase 2b SYMMETRY and Cohort D Complete Enrollment; Expecting Three Major Milestones in 2023; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

12/09/2022

Daily Note

Pages: 6

EFX Granted Breakthrough Therapy Designation in Less Than Three Months After Topline HARMONY Data; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

11/07/2022

Company Report

Pages: 10

3Q Recap; EFX Met Both Key NASH Endpoints in Phase 2b HARMONY Study; Cohort D Readout in 1H23; Raise PT to $64

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

08/08/2022

Company Report

Pages: 8

2Q Recap: We Remain Highly Confident in a Positive Top-line Data Readout for Phase 2b HARMONY Next Month; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Akero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

07/14/2022

Daily Note

Pages: 3

Healthcare Coverage Update - Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party